Security Snapshot

HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1 Institutional Ownership

CUSIP: 40637HAF6

13F Institutional Holders and Ownership History from Q3 2023 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

49

Principal

$439,034,460

Price (% of par)

128.33%

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 3 signals
Principal change
+$7,715,100
Market value change
+$8,065,864
Number of holders
49
Issuer context Names, identifiers, and filing context for this profile. 1 identity field
SEC-reported market price (% of par)
128.33%
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • 40637HAF6 - HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1 is tracked under CUSIP 40637HAF6.
  • 49 institutions reported positions in Q1 2026.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 55 to 49 between Q4 2025 and Q1 2026.
  • SEC-reported value moved from $573,383,607 to $564,714,249.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 49 institutions filings for Q1 2026.

Open SEC evidence

Security key

40637HAF6

Latest holder period

Q1 2026

13F holders

49

13D/G owners

0

CIK / CUSIP context first

As of 31 Mar 2026, 49 institutional investors reported holding $439,034,460 in principal (par value) of HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
11
Latest
Q1 2026
Rows shown
1-11 of 11
Period Principal Value Change Price (% of par) (Median) Investors
2026 Q1 $439,034,460 $564,714,249 +$8,065,864 128.33% 49
2025 Q4 $431,319,360 $573,383,607 -$303,578,944 132.8% 55
2025 Q3 $655,325,460 $920,432,391 +$102,237,538 140.75% 63
2025 Q2 $628,830,300 $718,645,608 -$27,561,128 114.08% 74
2025 Q1 $647,508,446 $828,761,473 +$4,645,168 128.11% 77
2024 Q4 $672,476,260 $730,001,496 -$62,779,579 108.09% 77
2024 Q3 $680,559,400 $810,707,471 +$105,250,543 118.98% 75
2024 Q2 $23,972,237,400 $717,063,397 -$3,930,381 111.16% 72
2024 Q1 $623,774,400 $607,993,350 -$28,940,823 97.4% 70
2023 Q4 $658,912,150 $616,721,993 -$3,988,874 93.09% 72
2023 Q3 $660,082,850 $622,263,753 +$620,529,779 93.71% 64
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .